A Phase 1 interventional study of Febuxostat and Inosine in Parkinson's Disease (PD), sponsored by Fujita Health University. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Fujita Health University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Parkinson Disease with a site in Japan — 9 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Japan.
Among the 75 studies in Parkinson Disease with a site in Japan, this one is the 49th largest by planned enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 in phase 1, and was the 72nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →9 of the 75 studies in Parkinson Disease with a site in Japan are open now. Recruiting first, the newest first:
AbbVie · Sites in Japan, United States, Canada and 6 more countries
Ages 18–69
University of Shizuoka · Sites in Japan
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in Japan, United States
Ages 30–85 · Healthy volunteers
Prevail Therapeutics · Sites in Japan, United States, Germany and 2 more countries
Ages 30–80 · Healthy volunteers
InSightec · Sites in Japan, United States
Ages 30–99
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 24 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 99 across the 60 interventional studies, 432 across the 15 observational. Of the 63 that completed or were terminated, 28 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 75 have an industry lead sponsor. The 10 most frequent:
Fujita Health University is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Fujita Health University has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Parkinson Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies in Parkinson Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:
Who can join: Adults with early-stage Parkinson's disease on stable medication regimens.
What participants do:
Risks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments.
Learn more: Contact [site-specific contact info] for details on eligibility and enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with Parkinson's disease by a specialist according to MDS-PD diagnostic criteria, and at pre-enrollment screening, all of the following are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive febuxostat and inosine (Dose Level 1) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Drug: Febuxostat · Drug: Inosine
Participants receive febuxostat and inosine (Dose Level 2) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Drug: Febuxostat · Drug: Inosine
Participants receive febuxostat and inosine (Dose Level 3) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Drug: Febuxostat · Drug: Inosine
Participants receive febuxostat and inosine (Dose level 4) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Drug: Febuxostat · Drug: Inosine
Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
Change in plasma hypoxanthine concentration from baseline to Week 12
The difference in plasma hypoxanthine level (µmol/L) between pre-dose at Day 0 and Week 12 visit.
Time frame: 12 weeks
Change in plasma hypoxanthine concentration from baseline to Week 4
The difference in plasma hypoxanthine level between pre-dose at Day 0 and Week 4 visit.
Time frame: 4 weeks
Change in cerebrospinal fluid (CSF) hypoxanthine concentration from baseline to Week 12
The difference in CSF hypoxanthine level between the pre-dose at Day 0 and the Week 12 visit.
Time frame: 12 weeks
Change in MDS-UPDRS Part III score from baseline to Week 12
The difference in Movement Disorder Society-Unified Parkinson's Disease Rating Scale motor examination (ON state) score between Day 0 and Week 12.
Time frame: 12 weeks
Change in Mini-Mental State Examination (MMSE) score from baseline to Week 12
The difference in MMSE score between Day 0 and Week 12.
Time frame: 12 weeks
Change in Geriatric Depression Scale-15 (GDS-15) score from baseline to Week 12
The difference in GDS-15 score between Day 0 and Week 12.
Time frame: 12 weeks
Plan to share: Yes — De-identified individual participant data (including the dataset and data dictionary) and the whole study protocol will be made available to qualified researchers beginning 6 months after publication and ending 3 years after publication. Requests should be directed to the corresponding author, Dr. Hirohisa Watanabe (email: hirohisa.watanabe@fujita-hu.ac.jp), with a research proposal and data use agreement. IPD Sharing Time Frame: Available 6 months to 3 years after publication. IPD Sharing Access Criteria: Qualified researchers with IRB/ethics approval and a signed data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Available 6 months to 3 years after publication of the primary results.
Access criteria: Qualified researchers who have obtained approval from their institutional review board or ethics committee and who sign a data use agreement with the study sponsor may request access to de-identified individual participant data, the full study protocol, statistical analysis plan, informed consent form, and analytic code. Requests should be submitted via email to the corresponding author, Dr. Hirohisa Watanabe (hirohisa.watanabe@fujita-hu.ac.jp), and include a brief research proposal and evidence of IRB/ethics approval.
Data sharing details ↗ · jrct.mhlw.go.jp
Started Jun 2025 (actual). Primary completion is estimated for Mar 2026, 9 months after the start.
Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 9 months is below that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Febuxostat · Inosine
Fujita Health University